Sofinnova Partners Appoints Two New Partners Strengthening Team of Next Generation Investors
Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the promotion to Partner of two exceptional team members, both of whom have served distinguished tenures at the firm, with expertise across different strategies. These promotions underscore Sofinnova's dedication to developing talent from within its own ranks and commitment to driving impactful change in the sector.
"We are delighted to announce the well-deserved promotions of Anta Gkelou and Guillaume Baxter to Partner level, recognizing their outstanding growth and expertise since joining us in 2017," said Antoine Papiernik, Managing Partner at Sofinnova Partners. "Their journeys exemplify our commitment to cultivating talent and investing in the future."
Gkelou joined Sofinnova as an Analyst in the Capital Strategy in 2017 after working as an immunology scientist at Danone Nutricia. She holds a PhD from Imperial College London where she worked on respiratory diseases at the National Heart and Lung Institute and conducted her post-doctoral research in heart failure post myocardial infarction at INSERM in France. Her strong interest in scientific discoveries and their development path to new products, alongside her ability to identify promising investment opportunities have contributed significantly to the firm's success. As a Partner in the Capital Strategy, Gkelou will play a key role in investing in the next generation of early-stage biotech companies.
"In my new role as Partner, I look forward to contributing to building companies that develop products with transformative effects on patients’ lives,” said Gkelou. "I am fully committed to the firm's continued success and up for the challenge of making a long-term meaningful impact.”
Baxter was one of the pioneering members of Sofinnova’s Industrial Biotech Strategy team. Joining as a Senior Associate in 2017, he has consistently demonstrated a strong passion for industrial biotechnology and impact investing. Baxter brings robust experience and valuable insights from the chemical industry, having held various positions at Solvay including Solvay Ventures, which further enhanced his understanding of the intersection between industry and investment practice. As Partner, Baxter will continue to leverage his enthusiasm to identify and support groundbreaking companies within the industrial biotech and renewable chemistry sectors to drive positive transformation across global industries.
"I am honored to have been part of the Industrial Biotechnology team since its early days," Baxter said. "As a Partner, I will continue to leverage my experience to support game changing companies in these sectors, while simultaneously focusing on establishing Sofinnova as a leading sustainable investor driving impactful change.”
These promotions further strengthen Sofinnova Partners' position as a leading venture capital firm in the life sciences sector, with a reinforced commitment to talent development and capital investment expertise. The firm remains dedicated to identifying and supporting innovative companies that have the potential to transform healthcare, improve patient outcomes, and drive sustainable solutions.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240422219891/en/
Contact information
Bommy Lee
Head of Communications
Sofinnova Partners
blee@sofinnovapartners.com
+33 (0) 6 47 71 38 11
North America
RooneyPartners LLC
Kate Barrette
kbarrette@rooneypartners.com
+1 212 223 0561
France
StrategiesImage
Anne Rein
anne.rein@strategiesimage.com
+33 (0) 6 03 35 92 05
United Kingdom
Optimum Strategic Communications
Hana Malik
sofinnova@optimumcomms.com
+44 (0) 20 3882 2119
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Announces Board Transitions and Management Update2.1.2025 13:00:00 CET | Press Release
Kinaxis® Inc. (“Kinaxis ” or the “Company ”) (TSX: KXS), a global leader in end-to-end supply chain orchestration, has, effective January 1, appointed Lynn Loewen to the Company’s Board of Directors and member of the Audit Committee. Due to current commitments, Betsy Rafael will not be seeking re-election to the Board at the 2025 annual general meeting. “I’m pleased to add an exceptionally qualified Director in Lynn, who will ensure we maintain the strength of the audit oversight function, while bolstering the Board in a number of ways,” said Robert (Bob) Courteau, chair and interim chief executive officer. “Betsy has been an exceptional board member and we fully respect that she has several other professional and personal commitments that are taking her time. We appreciate her significant efforts and contributions and wish her the very best.” Ms. Loewen is an accomplished business leader who has held several leadership positions, including at Bell Canada and Air Canada Jazz, as well a
Computershare Acquires CMi2i2.1.2025 12:09:00 CET | Press Release
Computershare Limited (ASX: CPU) has announced that it has acquired CMi2i Limited. CMi2i provides independent and trusted advice to boards, executives and advisors of some of the largest public companies around the world. The company’s investor intelligence services, including its bondholder offering, help companies to identify and engage with investors on complex, contested and high stakes issues. It employs around 20 people in London and has a presence in New York, Milan and Madrid. Fiona Chalmers, CEO Issuer Services at Computershare said: “Bringing CMi2i into the Computershare Group is an exciting development that will enhance our investor relations offering to clients. “The acquisition further demonstrates our commitment to giving companies around the world the edge in the increasingly crucial area of shareholder engagement and ownership intelligence. “CMi2i’s approach to capital markets is very well respected, and their services and systems will complement our wider offering very
Aeromexico Named the Most On-Time Global Airline in 2024:2.1.2025 11:00:00 CET | Press Release
Cirium, the world’s most trusted source of aviation analytics, today announced the winners of its 2024 On-Time Performance Review, celebrating airlines and airports that excelled in on-time and operational performance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250101214982/en/ Cirium On-Time Performance Review 2024 (Photo: Business Wire) Cirium’s Annual report is the gold standard for global airline and airport performance analytics. An on-time flight is defined as a flight that arrives within 14:59 minutes of the scheduled gate arrival time. Airports measure punctuality as departing flights within 14:59 minutes of their scheduled departure time. Mexico’s Flag Carrier Tops Global Rankings Aeromexico claimed the prestigious title of the most On-Time “Global Airline” in 2024, achieving an impressive On-Time performance rate of 86.70%. Saudia followed closely as the runner-up with 86.35%, while Delta Air Lines secured thir
PQE Group Joins Project-COMFORT to Advance Patient-Centric Blood Collection and Diagnostics30.12.2024 07:50:00 CET | Press Release
PQE Group, a global consulting firm specializing in Life Sciences, is proud to contribute its expertise as a strategic partner in the Project-COMFORT consortium. This innovative public-private partnership, funded by Horizon Europe and supported by the Innovative Health Initiative Joint Undertaking (IHI JU), officially launched in November 2024, marking a transformative shift in blood collection and diagnostics. The ambitious 42-month project brings together 51 organizations from a broad spectrum of sectors, including academia, research institutions, hospitals, foundations, SMEs, medical technology, and pharmaceutical companies, all united by the mission to simplify, reduce the invasiveness of, and increase accessibility to blood collection through cutting-edge, patient-centered microsampling technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241229266268/en/ Follow Project-Comfort LinkedIn Page: https://www.linkedin.
Medical-Fish-Skin Company Kerecis Expands Silicone Fish-Skin Combination Product Range for Surgical and Trauma Wound with SurgiClose® Silicone27.12.2024 20:00:00 CET | Press Release
Kerecis, the company pioneering the use of sustainably sourced fish skin and fatty acids in cellular therapy and tissue regeneration and protection, today announced the availability of SurgiClose® Silicone, which combines a fish-skin graft and silicone backing for efficient treatment of surgical and trauma wounds. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241227975454/en/ SurgiClose® Silicone (Photo: Business Wire) SurgiClose® Silicone is a part of the SurgiClose® product family, which is intact fish-skin intended for the management of trauma wounds and surgical wounds in the operating room. The new product is available in two variations, SurgiClose® Silicone Adhesive with borders that overlap the fish-skin underneath and SurgiClose® Silicone Standard with non-overlapping borders. “Applying Kerecis fish-skin to a surgical or trauma wound is a multi-step process that often requires supporting products such as sutures, st
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom